According to preclinical work by Spanish researchers, carried out with the help of Rozen Le Panse’s team at the Institute of Myology :
- intraperitoneal injection of acetylcholine receptors (RACh) encapsulated in liposomes rich in phosphatidylserine decreases the anti-RACh antibody level and improves physical performance (Global clinical score or GCS) in an myasthenia gravis experimental mouse model;
- this original method for restoring self-tolerance is based on a physiological process, efferocytosis;
- the same researchers have also used it, still at the preclinical stage, in type 1 diabetes, multiple sclerosis and rheumatoid arthritis.
Other teams have already taken this approach in myasthenia with anti-RACh or anti-MuSK, without using liposomes.
